{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:45:53Z","timestamp":1791240353718,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A2015391"],"award-info":[{"award-number":["2017R1A5A2015391"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016R1C1B2008772"],"award-info":[{"award-number":["2016R1C1B2008772"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1I1A2A01062430"],"award-info":[{"award-number":["2019R1I1A2A01062430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Glioblastoma is an actively growing and aggressive brain tumor with a high propensity of recurrence. Although the surgical removal of tumor mass is the primary therapeutic option against glioblastoma, supportive pharmacotherapy is highly essential due to incredibly infiltrative characteristic of glioblastoma. Temozolomide, an FDA-approved alkylating agent, has been used as a first-line standard pharmacological approach, but several evident limitations were repeatedly reported. Despite additional therapeutic options suggested, there are no medications that successfully prevent a recurrence of glioblastoma and increase the five-year survival rate. In this study, we tested the possibility that finasteride has the potential to be developed as an anti-glioblastoma drug. Finasteride, an FDA-approved medication for the treatment of benign prostate hyperplasia and androgenic alopecia, is already known to pass through the blood\u2013brain barrier and possess antiproliferative activity of prostate epithelial cells. We showed that finasteride inhibited the maintenance of glioma stem-like cells and repressed the proliferation of glioblastoma. Mechanistically, finasteride lowered intracellular ROS level by upregulating antioxidant genes, which contributed to inefficient \u03b2-catenin accumulation. Downregulated \u03b2-catenin resulted in the reduction in stemness and cell growth in glioblastoma.<\/jats:p>","DOI":"10.3390\/pharmaceutics13091410","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T21:47:38Z","timestamp":1630964858000},"page":"1410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells"],"prefix":"10.3390","volume":"13","author":[{"given":"Hyeon Ji","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-995X","authenticated-orcid":false,"given":"Tae-Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Gyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaeeun","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hwa","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-1060","authenticated-orcid":false,"given":"Wanil","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Department of Convergence Medical Science, Institute of Health Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ha","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cosmetic Science and Technology, Daegu Haany University, Gyeongsan 38610, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2200-7396","authenticated-orcid":false,"given":"Do-Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kim, H.J., and Kim, D.Y. (2020). Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies\/Features. Molecules, 25.","DOI":"10.3390\/molecules25204641"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fisher, J.P., and Adamson, D.C. (2021). Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030324"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lara-Velazquez, M., Al-Kharboosh, R., Jeanneret, S., Vazquez-Ramos, C., Mahato, D., Tavanaiepour, D., Rahmathulla, G., and Quinones-Hinojosa, A. (2017). Advances in Brain Tumor Surgery for Glioblastoma in Adults. Brain Sci., 7.","DOI":"10.3390\/brainsci7120166"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"309","article-title":"Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer","volume":"5","author":"Baker","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41419-019-2200-2","article-title":"Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma","volume":"11","author":"Rabe","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.cdd.4401359","article-title":"Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells","volume":"11","author":"Kanzawa","year":"2004","journal-title":"Cell Death Differ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fneur.2020.01036","article-title":"Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): A randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kim, T.J., Kwon, H.S., Kang, M., Leem, H.H., Lee, K.H., and Kim, D.Y. (2018). The Antitumor Natural Compound Falcarindiol Disrupts Neural Stem Cell Homeostasis by Suppressing Notch Pathway. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113432"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-07-6878","article-title":"Temozolomide preferentially depletes cancer stem cells in glioblastoma","volume":"68","author":"Beier","year":"2008","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Leung, H.W., Leung, C.O., Lau, E.Y., Chung, K.P.S., Mok, E.H., Lei, M.M.L., Leung, R.W.H., Tong, M., Keng, V.W., and Ma, C. (2021). EPHB2 activates beta-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-21-0184"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1242\/dev.040451","article-title":"A directional Wnt\/beta-catenin-Sox2-proneural pathway regulates the transition from proliferation to differentiation in the Xenopus retina","volume":"136","author":"Agathocleous","year":"2009","journal-title":"Development"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0960-9822(03)00240-9","article-title":"Zebrafish prickle, a modulator of noncanonical Wnt\/Fz signaling, regulates gastrulation movements","volume":"13","author":"Veeman","year":"2003","journal-title":"Curr. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41419-020-02988-8","article-title":"Wnt\/beta-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma","volume":"11","author":"Yun","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"D419","DOI":"10.1093\/nar\/gky1038","article-title":"PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools","volume":"47","author":"Mi","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"D330","DOI":"10.1093\/nar\/gky1055","article-title":"The Gene Ontology Resource: 20 years and still GOing strong","volume":"47","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/toxsci\/kfm156","article-title":"A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals","volume":"99","author":"Fielden","year":"2007","journal-title":"Toxicol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1091\/mbc.e03-01-0865","article-title":"Beta-catenin regulation during the cell cycle: Implications in G2\/M and apoptosis","volume":"14","author":"Olmeda","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.18632\/oncotarget.3131","article-title":"Inhibition of PI3K\/AKT\/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells","volume":"6","author":"Hambright","year":"2015","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ncb1405","article-title":"The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled","volume":"8","author":"Funato","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/emboj.2010.292","article-title":"ROS-mediated amplification of AKT\/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(\u2212\/\u2212) mice","volume":"29","author":"Yalcin","year":"2010","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5301\/ijbm.5000301","article-title":"EGFR as a clinical marker in glioblastomas and other gliomas","volume":"33","author":"Saadeh","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/brain\/awp093","article-title":"Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death","volume":"132","author":"Ronellenfitsch","year":"2009","journal-title":"Brain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8813","DOI":"10.2147\/OTT.S262359","article-title":"Dihydrotestosterone Induces Proliferation, Migration, and Invasion of Human Glioblastoma Cell Lines","volume":"13","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108556","DOI":"10.1016\/j.steroids.2019.108556","article-title":"The effect of finasteride and dutasteride on the synthesis of neurosteroids by glioblastoma cells","volume":"155","author":"Valdez","year":"2020","journal-title":"Steroids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43452","DOI":"10.18632\/oncotarget.6171","article-title":"Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing","volume":"6","author":"Patil","year":"2015","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4143\/crt.2018.249","article-title":"Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro","volume":"51","author":"Koh","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Arthurs, A.L., Keating, D.J., Stringer, B.W., and Conn, S.J. (2020). The Suitability of Glioblastoma Cell Lines as Models for Primary Glioblastoma Cell Metabolism. Cancers, 12.","DOI":"10.21203\/rs.3.rs-56880\/v1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbrc.2018.02.083","article-title":"Cellular toxicity driven by high-dose vitamin C on normal and cancer stem cells","volume":"497","author":"Kim","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.aaa5004","article-title":"Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH","volume":"350","author":"Yun","year":"2015","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/0008-5472.CAN-15-2121","article-title":"The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)","volume":"76","author":"Tsuchihashi","year":"2016","journal-title":"Cancer Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:57:34Z","timestamp":1760165854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["pharmaceutics13091410"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13091410","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}